natgillin/translations-raw huggingface dataset:
A radio communication base station (100) for receiving an aperiodic sounding reference signal, A-SRS, comprising: 
Radio komunikacijski terminalni uređaj (300) za odašiljanje aperiodičnog referentnog signala sondiranja, A-SRS, sadržeći:
A pharmaceutical composition comprising an oligonucleotide according to any of claims 1 to 5. 
Farmaceutski sastav koji sadrži nukleotid prema patentnom zahtjevu 1 ili 2.
The method according to claim 1, wherein the FGF-18 compound is administered once monthly for 3 consecutive months. 
Spoj FGF-18 za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što se spoj FGF-18 treba primijeniti jednom mjesečno tijekom 3 uzastopna mjeseca.
In a corresponding way, the invention relates also to a method for decoding a data signal representative of at least one image split into partitions which has been previously encoded, comprising a step for obtaining, by the entropy decoding of data of the signal, digital information items associated with residual data items relating to at least one previously encoded partition. Such a decoding method is notable in that it comprises the following steps: 
Postupak dekodiranja signala podataka (F) koji predstavlja barem jednu sliku podijeljenu u particije koja je bila prethodno kodirana, koji sadrži korak dobivanja (D2), pomoću entropijskog dekodiranja stavki podataka za navedeni signal, digitalnih informacija povezanih sa preostalim stavkama podataka koje se odnose na barem jednu prethodno kodiranu particiju, te je skup preostalih stavki podataka postavljen u blok preostalih stavki podataka, te je navedeni postupak dekodiranja naznačen time da sadrži slijedeće korake:
It is believed that volatile sulphur-containing compounds are responsible for the sunstruck flavour. 
Vjeruje se da su hlapljivi spojevi koji sadržavaju sumpor odgovorni za užeglu aromu.
Likewise particularly preferably, the pharmaceutical compositions or vaccines can be used for the treatment of cancer or tumour diseases, preferably selected from colon carcinomas, melanomas, renal carcinomas, lymphomas, acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), gastrointestinal tumours, pulmonary carcinomas, gliomas, thyroid tumours, mammary carcinomas, prostate tumours, hepatomas, various virus-induced tumours such as, for example, papilloma virus-induced carcinomas (e.g. 
RNA molekula prema zahtjevu 1 naznačena time da je za uporabu za liječenje kanceroznih bolesti, autoimune bolesti, alergija ili zaraznih bolesti, pri čemu su kancerozne bolesti poželjno odabrane iz skupine koja sadrži karcinom debelog crijeva, melanom, karcinom bubrega, limfom, akutnu mijeloidnu leukemiju (AML), akutnu limfoidnu leukemiju (ALL), kroničnu mijeloidnu leukemiju (CML), kroničnu limfocitnu leukemiju (CLL), gastrointestinalne tumore, karcinome pluća, gliome, tumore štitnjače, karcinome dojke, tumore prostate, hepatome, razne tumore uzrokovane virusima kao što su, na primjer, karcinomi uzrokovani papiloma virusom (npr.
each RI is independently selected from the group consisting of alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aminocarbonyl, alkyloxycarbonyl, carbocyclylcarbonyl, and heterocyclylcarbonyl, wherein: the alkylcarbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and 
alkilkarbonil, alkenilkarbonil i alkinilkarbonil su opcijski supstituirani s jednim ili više supstituenata neovisno odabranima iz skupine koju sačinjavaju karboksi, hidroksi, halo, amino, nitro, azido, okso, aminosulfonil, alkiloksikarbonil, alkeniloksikarbonil, alkiniloksikarbonil, alkilkarboniloksi, alkenilkarboniloksi, alkinilkarboniloksi, alkiloksi, alkeniloksi, alkiniloksi, karbociklil, heterociklil, cijano i aminokarbonil, i aminokarbonil je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju alkil, alkenil, alkinil, alkiloksialkil, karbociklil, heterociklil, alkilsulfonil i alkilsulfonilamino, pri čemu:
The garment according to claim 1, wherein the garment is a pair of stretchy denim fabric trousers. 
Odjevni predmet, u skladu s patentnim zahtjevom 1, naznačen time, da je to par hlača od elastične traper tkanine.
The method of claim 9, further comprising amplifying the fragments on said solid support by providing a polymerase and an amplification primer corresponding to a portion of the first polynucleotide. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što dodatno uključuje amplificiranje fragmenata na navedenoj čvrstoj površini dodavanjem polimeraze i amplifikacijske početnice koja odgovara dijelu prvog polinukleotida.
The apparatus of claim 1, wherein the housing is configured to enable a user to inhale the first substance, and the first substance comprises a. liquid drug. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kućište (112) konfigurirana tako da korisniku omogućuje udisanje prve tvari i pri čemu prva tvar sadrži nikotin.
Preferred sweeteners include, but are not limited to, artificial sweeteners such as aspartame, saccharin, and cyclamates; natural sweeteners such as sucrose, fructose, glucose, lactose, maltodextrin, and sodium glycolate; and mixtures of artificial and natural sweeteners, such as a mixture of aspartame and sucrose. 
Povoljni zaslađivači uključuju, ali nisu ograničeni na, umjetna sladila poput aspartama, saharina i ciklamata; prirodna sladila poput saharoze, fruktoze, glukoze, laktoze, maltodekstrina 1 natrij glikolata; te isto tako i smjese umjetnih 1 prirodnih sladila, poput smjese aspartama i saharoze.
In the non-activated test system, treatment was for approximately 3 hr and for 20 hr and in the S9 activated test system, exposure was for 3 hr.7,8 
U ne-aktiviranom test sustavu tretman je bio približno 3 sata i 20 sati i u S9 aktiviranom test sustavu, izlaganje je bilo 3 sata. "ž
Apparatus according to claim 2, wherein said ramps, said mechanical connections, said articulated poles, said auxiliary shaft said support are so sized, positioned and arranged among them that the removing/approaching of said movable frame with respect to said fixed structure causes a translation-rotation shift which draws a like motion to the axes of the rotating shafts, which determine that the ramps related to the same rotating shaft are able of shift on a plane substantially orthogonal to the respective rotation shaft, and with a motion comprising the change of the ramp inclination on the respective groove. 
Uređaj prema zahtjevu 2, naznačen time da su navedene rampe, navedeni mehanički spojevi, navedeni zglobni stupovi, navedena pomoćna osovina, navedena nosiva sredstva tako dimenzionirani, smješteni i postavljeni između njih da uklanjanje/približavanje navedenog pomičnog okvira s obzirom na navedenu nepomičnu strukturu uzrokuje translacijski-rotacijski pomak koji prenosi slično gibanje na osi rotirajućih osovina, koje određuju da se rampe povezane na istu rotacijsku osovinu (32C) mogu pomicati u ravnini koja je uglavnom ortogonalna na odgovarajuću rotacijsku osovinu, te uz gibanje koje sadrži promjenu nagiba rampe na odgovarajućem žljebu.
The topical veterinary composition of clause 11, wherein the at least second active agent is an insect growth regulator. 
Topikalni veterinarski pripravak prema zahtjevu 8, naznačen time, da najmanje druga djelatna tvar je regulator rasta kukaca.
represents a hydrogen atom; 
-R? predstavlja atom vodika
A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol, odabrana iz grupe koja se sastoji od:
adding the aliquot of protein carrier required over a period of 5 minutes to 6 hours, wherein at least one quarter of the aliquot is added over the first half of the period, and at least one quarter of the aliquot over the second half of the period; 
Imunogeni pripravak, naznačen time što sadrži konjugat saharida Hib i najmanje dva dodatna konjugata bakterijskih saharida, gdje konjugat Hib je prisutan u manjoj dozi saharida od srednje doze saharida za sve od najmanje dva dodatna konjugata bakterijskih saharida.
is a C1-5 fluoroalkyl; and PG is a protecting group, the method comprising the step of reacting a compound of formula (IIa) with a compound of formula (VIII): wherein PG of formula (IIIa) is a group of formula SiR33. 
je C1-5 fluoroalkil; i PG je zaštitna skupina, postupak sadrži korak reakcije spoja formule (IIa) sa spojem formule (VIII):
is 0, or 1 and when p is 0 then a direct bond is intended; 
pje 0, ili 1 i kada p je 0 tada je namjeravana direktna veza;
The pharmaceutical composition of claim 5, further comprising a therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti-infective agent, a targeting agent and an adjunct compound. 
Oblik prema zahtjevu 31, koji dalje sadrži terapijsko sredstvo izabrano između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže i inhibira taj inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja.
where n=5 to 9. The silylated derivative of the general formula IV is treated with tetrabutylammonium fluoride affording alkenol of the general formula V, 
IV, gdjen=5do9 na silirani derivat opće formule IV djeluje tetrabutilamonij fluorid pri nastanku alkenola opće formule V, o 5
Recent work suggests that nicotinic acid probably acts through a specific GPCR [Lorenzen A, et al. 
Noviji radovi ukazuju da nikotinska kiselina vjerojatno djeluje preko specifičnog GPCR [Lorenzen, A i sur.
In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. 
U takvim oblicima, pripravak je podijeljen u jedinične doze koje sadrže odgovarajuće količine aktivnog sastojka.
A 10-minute pre-treatment with 10 mg/kg of dextromethorphan caused no significant tremor inhibition, but significantly increased the inhibitory action of 40 or 60 mg/kg tolperisone. 
Prethodna obrada s 10 mg/kg dekstrometorfana u trajanju od 10 minuta nije uzrokovala značajnu inhibiciju tremora, već je značajno povećala inhibitorsko djelovanja od 40 ili 60 mg/kg tolperisona (tablica 3.
Item 37: A chimeric polypeptide comprising: a polypeptide having a sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17; and 
Humanizirano protutijelo anti-CD20 tipa II, naznačeno time, da obuhvaća sljedeće: varijabilno područje jakog lanca odabrano iz skupine koju čine SEQ ID NO:32 1 SEQ ID NO:40, 1 varijabilno područje KV1 slabog lanca od SEQ ID NO:76.
guiding and folding means (23) suitable for cooperating with said sewing machine, and for preparing said gusset (14') folded lengthwise into two parts and positioning it ready folded on the edge of the mattress panel (1') internal to the mattress cover, to enable the stitching the gusset onto the mattress panel, along said first seam (15) inwardly recessed from the edge of the mattress panel, in correspondence with said fold dividing the gusset into two parts; 
vodilice i sredstva za presavijanje (23) prikladni za suradnju sa šivaćim strojem, i za pripremu ušitka (14’) koji je po dužini presavijen na dva dijela, i njegovo postavljanje na rub obloge madraca (1’) s unutarnje strane presvlake madraca, radi omogućavanja šivanja ušitka na oblogu madraca, duž prvog šava (15) okrenutog prema unutra od ruba obloge madraca, što odgovara mjestu gdje mjesto presavijanja dijeli ušitak na dva dijela;
covalently linking a poly (ethylene glycol) residue at the N-terminus of erythropoietin and/or an internal lysine residue of erythropoietin using an activated reagent for covalently linking a poly (ethylene glycol) residue at the N-terminus of erythropoietin and/or an internal lysine residue of a molecular weight of from 20 kDa to 40 kDa, 
kovalentno vezanje poli (etilenglikol) ostatka na N-kraju eritropoietina i/ili internog lizinskog ostatka eritropoietina s uporabom aktiviranog reagensa za kovalentno vezanje poli (etilenglikol) ostatka na N-kraju eritropoietina i/ili internog lizinskog ostatka molekulske mase od 20 kDa do 40 kDa,
Device according to claim 5, characterised in that the second guide arm (18) is curved in the shape of a question mark, whereby the first end (19) connects to the cable passage (10). 
Uređaj sukladno zahtjevu 5, naznačen time što je druga vodeća ruka (18) zakrivljena u obliku upitnika, pri čemu prvi kraj (19) povezuje s prolazom kabela (10).
The treatment effective amount of an anti-Alzheimer's disease active agent for use as in claim 4 or claim 5, wherein said genetic variant of the TOMM40 gene is a poly-T insertion variant at genomic location 50,094,889 of NCBI Build 36.3_(rs10524523). 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, za uporabu prema zahtjevu 4 ili zahtjevu 5, naznačeno time, da navedena genetička varijanta od TOMM40-gena je poli-T umetnuta varijanta na genomskom mjestu 50,094,889 od NBCI-Build 36.3 (rs10524523).
Such a communication module 19 may be constituted, for example, by a “DLL”. 
Takav komunikacijski modul 19 može biti načinjen, na primjer, pomoću "DLL".
Use according to aspect 12, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period. 
Upotrcba prema zahtjevu 12, gdje je prije stupnja (a), spomenutom pacijentu davan pirfenidon u dozama nižim od 2400 mg/dan u tijeku vremenskog perioda.
Pressure tank, according to claim 4, characterized in that the data plate (15) has shoulders (15a) on edges. 
Spremnik pod pritiskom prema zahtjevu 4, naznačen time da podatkovna ploča (15) na rubovima ima izbočine
The use according to item 26, wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain, pain due to osteoarthritis, pain due to arthritis, pain due to rheumatoid arthritis, cancer pain, pain due to spinal cord injury, surgical pain, post-operative pain or acute pain. 
Uporaba prema zahtjevu 9, naznačena time da bol je odabrana iz skupine koja sadrži kroničnu bol, neuropatsku bol, upalnu bol, bol zbog osteoartritisa, bol zbog artritisa, bol zbog reumatoidnog artritisa, bol zbog karcinoma, bol zbog ozljede leđne moždine, operativnu bol, postoperativnu bol ili akutnu bol.
adjusting the pressure in a space between the provisions and the air-tight covering (3) to a second value, lower than the first value, for creating the channels outside the circumference of the air-tightly covered reinforcement package; 
- < namještanje pritiska u prostoru između pomoćnih sredstava i neprodušnog pokrova (3) na drugu vrijednost, nižu od prve vrijednost, za stvaranje kanala izvan opsega neprodušnog pokriven tijelo za ojačanje;
valve means (50) to intercept the flow of air flowing towards said delivery openings (21, 22) and allow the discharging of air alternatively through said first delivery opening (21) or said second delivery opening (22), wherein: 
sredstva za reguliranje protoka (50) za presjecanje struje zraka usmjerene prema navedenim otvorima za ispuhivanje (21, 22) i omogućavanje ispuhivanja zraka alternativno kroz navedeni prvi otvor za ispuhivanje (21) ili drugi otvor za ispuhivanje (22), pri čemu:
The recombinant adenosine deaminase of claim 15, wherein the adenosine deaminase-mediated condition is severe combined immune disorder. 
Rekombinantna adenozin deaminaza u skladu s patentnim zahtjevom 15, naznačena time, da je patološko stanje posredovano adenozin deaminazom teška kombinirana imunodeficijencija.
The method of claim 16, wherein the first detector comprises an Fc-binding molecule conjugated to a first detectable entity, and wherein the Fc-binding molecule is protein A and/or protein G. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što prvi detektor sadrži molekulu koja se veže na Fc, konjugiranu s prvim detektibilnim entitetom, te što je molekula koja se veže na Fc protein A i/ili protein G.
The pharmaceutical composition according to claim 3, wherein composition is in a fixed or free combination for simultaneous, sequential or separate administration together with acceptable excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application. 
Farmaceutski proizvod sukladno bilo kojem od patentnih zahtjeva 5 do 7, naznačen time, da je djelatna tvar nazočna u fiksiranoj ili slobodnoj kombinaciji za istovremeno, povremeno ili odvojeno davanje zajedno s uobičajenim ekscipijensima, adjunktima i aditivima u farmaceutskom obliku prikladnome za inhalatornu primjenu.
transmit a second downlink signal comprising an uplink access configuration index, the uplink access configuration index identifying an uplink access configuration from among the indicated plurality of uplink access configurations, and subsequently receive a random access transmission from a first wireless device according to the random access configuration included in the identified uplink access configuration; 
slanje drugog signala silazne veze koji sadrži indeks konfiguriranja pristupa uzlaznoj vezi, gdje indeks konfiguriranja pristupa uzlaznoj vezi identificira konfiguriranje pristupa uzlaznoj vezi između ukazanih više konfiguriranja pristupanja uzlaznoj vezi, te zatim primanje slanja sa slobodnim pristupom iz prvog bežičnog uređaja u skladu s konfiguriranjem sa slobodnim pristupom uključenim u identificirano konfiguriranje pristupa uzlaznoj vezi;
Figs. 10-12 shows cross-sectional views of the packaging, and 
Slike 10-12 prikazuju pogled na pakiranje u poprečnom presjeku, Slike 13-22E prikazuju crteže izgleda pakiranja,
Purification of the crude by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 95/5 gave the compound in the form of free base which was transformed into its hydrochloride salt to give 0.045g of pure product. 
Pročišćavanje sirovog produkta kromatografijom na silikagelu, uz eluiranje smjesom diklormetan/metanol, u odnosima od 100/0 do 95/5, daje spoj u obliku slobodne baze, koju se pretvori u njenu hidrokloridnu sol kako bi se dobilo 0,045 g čistog produkta.
Drawings are not deemed necessary inasmuch as the following description will enable any person skilled in the art to make use of the invention. 
Crteži nisu smatrani neophodnim, pošto će sljedeći opis omogućiti da svaka tehnički kvalificirana osoba primjeni izum.
The method according to claim 1, wherein a controller (45) transmits a deactivation command signal to a motor actuator (44) of the downhole pump if the correct depth indication signal has not been received for a predetermined period of time. 
Metoda u skladu sa patentnim zahtjevom 1, gdje kontroler (45) odašilje komandni signal za deaktivaciju do aktuatora (44) motora pumpe za bušotinu ukoliko ispravan signal indikacije dubine nije primljen tijekom unaprijed određenog vremenskog perioda.
The medium according to the invention preferably further comprises inorganic salts and trace elements. 
Poželjno je da medij sukladan izumu nadalje sadrži anorganske soli i elemente u tragovima.
The pharmaceutical solid preparation according to claim 1, wherein the amount of the sugar and/or the sugar alcohol is 0.1 to 10 parts by weight based on 1 part by weight of the methacrylic acid-based enteric polymer. 
Čvrsti farmaceutski pripravak prema zahtjevu 1, naznačen time, da je količina šećera i/ili šećernog alkohola određena na 0,1 do 10 masenih dijelova prema 1 masenom dijelu enteričkog polimera na bazi metakrilne kiseline.
converting a compound of formula (I-i) to a compound of formula (I) wherein the link between C7 and C8 in the macrocycle is a single bond, i.e. a compound of formula (I-j): by a reduction of the C7-C8 double bond in the compounds of formula (I-j); 
' > (b) pretvorbe spoja formule (I-i) u spoj formule (1) pri čemu veza između C7 i Cg u makrociklu je jednostruka veza, na primjer spoj formule (I-j): oF
The compound or composition for use according to claim 1, wherein the disease or disorder is bone cancer, hematologic cancer, or fallopian tube cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak želudca.
Tiotropium bromide solvate with 1,3-propanediol. 
Solvat tiotropij bromida, naznačen time, da je s 1,3-propanediolom.
It is important to note that in naturally-occurring rapamycin, the 41-methoxy and 42-hydroxy substituents exist in a trans configuration relative to each other. 
Važno je uočiti da u prirodnom rapamicinu 41-metoksi i 42-hidroksi supstituenti stoje međusobno u frans-konfiguraciji.
(d1) carrying out at least one crystallization sub-stage (14", 14"') with at least a part of the fifth fraction obtained in method step (b2), wherein to the fifth fraction prior to the crystallization in method step (c1) more than 100% by weight of solvent relative to the weight of the fifth fraction are added, to prepare a ninth fraction containing deoiled heavy wax having an oil content of at most 5% by weight and a kinematic viscosity of more than 7 cSt and a tenth fraction containing heavy soft wax having an oil content of more than 5% by weight and a kinematic viscosity of more than 7 cSt. 
(d,) provođenje najmanje jednog podstupnja kristalizacije (14", 14"') s barem dijelom dobivene pete frakcije u koraku metode (b2), pri čemu se petoj frakciji prije kristalizacije u koraku metode (cy) dodaje više od 100% masenog udjela otapala u odnosu na težinu pete frakcije, za pripremu devete frakcije koja sadrži oduljeni teški vosak koji ima najviše 5% masenog udjela ulja 1 kinematičku viskoznost veću od 7 cSt i desete frakcije koja sadrži teški meki vosak s udjelom ulja većim od 5% masenog udjela i kinematičkom viskoznošću većom od 7 cSt.
See also European Patent No. 
Broj europske prijave patenta:
A package as claimed in any one of Claims 1 to 8, and comprising a soft outer package partly enclosing the inner package (3) and leaving at least a top wall of the inner package (3) free. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time, da sadrži mekano unutarnje pakiranje u koje je djelomično umetnuto unutarnje pakiranje (3), a najmanje gornja stjenka unutarnjeg pakiranja (3) ostaje slobodna.
The mixture was cooled to +50°C and then stirred for 3h. 
Smjesa je ohlađena do +5%C 1 onda je miješana u tijeku 3 sata.
curing the coating by heat activation 
- - otvrdnjavanje prevlake toplinskom aktivacijom.
The method of claim 1, wherein said follicular lymphoma (FL), or mantle cell lymphoma (MCL) is characterized by a B/T-cell ratio of less than 1:5. 
Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent karakteriziran omjerom B/T stanica manjim od 1:5.
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Preferably, the photocatalytic composition comprises: 
Fotokatalitički sastav zasnovan na cementu koji sadrži: